Table 5 Comparison of Response in HBsAg-positive patients treated with or without rituximab
From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
| Â | Use of rituximab (N = 27) (33.3%) | No rituximab (N = 54) (66.7%) | p-value |
|---|---|---|---|
Complete response | 19 (70.4) | 24(44.4) | 0.16 |
Partial response | 6 (22.2) | 25(46.3) | Â |
Stable disease | 1(3.7) | 3(5.6) | Â |
Progressive disease | 1(3.7) | 2(3.7) | Â |